Glucocorticoid-induced osteoporosis: head-to-head drug study results

Denosumab is superior to risedronate in increasing bone-mineral density (BMD) at the lumbar spine in patients just starting or continuing steroid therapy, according to 12-month results of a 24-month randomised controlled study.

The researchers compared the efficacy and safety of denosumab and risedronate in more than 750 patients with glucocorticoid-induced osteoporosis at 79 centres in Europe, Latin America, Asia and North America.

More than 500 patients were on at least 7.5mg prednisone daily (or equivalent) for at least three months (glucocorticoid